365 related articles for article (PubMed ID: 30845885)
1. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
Liu M; Husain S; Famure O; Li Y; Kim SJ
Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
[TBL] [Abstract][Full Text] [Related]
2. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
[TBL] [Abstract][Full Text] [Related]
3. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
4. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
[TBL] [Abstract][Full Text] [Related]
5. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
6. Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Sprangers B; Riella LV; Dierickx D
Am J Kidney Dis; 2021 Aug; 78(2):272-281. PubMed ID: 33774079
[TBL] [Abstract][Full Text] [Related]
7. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
8. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
[TBL] [Abstract][Full Text] [Related]
9. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
Wong JY; Tait B; Levvey B; Griffiths A; Esmore DS; Snell GI; Williams TJ; Kotsimbos TC
Transplantation; 2004 Jul; 78(2):205-10. PubMed ID: 15280679
[TBL] [Abstract][Full Text] [Related]
11. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
13. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE
J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
[TBL] [Abstract][Full Text] [Related]
15. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
Huang JG; Tan MYQ; Quak SH; Aw MM
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29071779
[TBL] [Abstract][Full Text] [Related]
18. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
[TBL] [Abstract][Full Text] [Related]
20. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]